Eli Lilly started the 2026 fiscal year with record-breaking numbers, driven by surging demand for its obesity and diabetes portfolio. The company’s quarterly performance has led to a significant upward revision of its full-year financial outlook.
1. Robust Financial Growth
Q1 2026 revenue reached $19.8 billion, a 56% increase year-over-year, surpassing consensus estimates by $2.4 billion.
-
Mounjaro: Generated $8.7 billion, a 125% surge compared to Q1 2025.
-
Zepbound: Contributed $4.2 billion, marking an 80% growth. Consequently, Eli Lilly raised its 2026 revenue guidance to a range of $82 billion to $85 billion, adding $2 billion to its previous forecast.
2. Early Success of Foundayo (Orforglipron)
This quarter marked the debut of Foundayo, Lilly’s oral GLP-1RA for weight loss. Early indicators suggest a strong market entry:
-
Broad Availability: Launched in pharmacies on April 9 and integrated into over 12 major telehealth platforms.
-
Prescriber Adoption: Over 8,000 healthcare providers have already prescribed Foundayo, with 33% being new to oral GLP-1 therapies.
-
Strategic Advantage: While competing with Novo Nordisk’s oral Wegovy, Foundayo benefits from superior ease-of-use, specifically the lack of meal restrictions, which analysts believe will drive significant market share.
3. Aggressive M&A Strategy
Eli Lilly remains one of the most active players in pharmaceutical business development.
-
The company has completed six M&A deals so far in 2026, totaling approximately $21 billion in investment.
-
The recent $2.3 billion acquisition of Ajax Therapeutics signals an expansion into specialized hematology, complementing its core metabolic franchise.
CEO Dave Ricks emphasized that the company will remain active in seeking external opportunities to bolster its internal pipeline and sustain long-term growth.